Peter Altmaier (l), Federal Minister of Economics and Technology, and Ulrich Nu'baum (r), State Secretary in the Federal Ministry of Economics, take part in a press conference with Franz-Werner Haas (on screen), CEO of the biotech company Curevac, and the investor Hopp.

GSK, Ger­many push coro­n­avirus-fo­cused mR­NA play­er Cure­Vac's lat­est round to $640M

Af­ter court­ing some high-pro­file in­vestors, Cure­Vac has closed a whop­ping $640 mil­lion (€560 mil­lion) in its lat­est round.

The biotech an­nounced the fi­nanc­ing in a brief press re­lease, not­ing that pre­vi­ous­ly dis­closed in­vest­ments from the Ger­man fed­er­al gov­ern­ment and Glax­o­SmithK­line ac­count­ed for $514 mil­lion of the to­tal. Qatar In­vest­ment Au­thor­i­ty and oth­er ex­ist­ing as well as new in­vestors con­tributed the rest.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA